Evidence map›Paper›PMID 27822706›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2017

Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.

Miodrag Dragoj, Zorica Milosevic, Jasna Bankovic, Nikola Tanic, Milica Pesic, Tijana Stankovic

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Review
  3. CXCR4/CXCL12 blockade therapy; a new horizon in TNBC therapy.Medical oncology (Northwood, London, England) · 2025
    Review
  4. The Impact of Pdcd4, a Translation Inhibitor, on Drug Resistance.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review.Journal of experimental & clinical cancer research : CR · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Miodrag DragojInstitute for Biological Research "Sinisa Stankovic", Department of Neurobiology, University of Belgrade, Despota Stefana 142, Belgrade, 11060, Serbia.
Zorica MilosevicInstitute for Biological Research "Sinisa Stankovic", Department of Neurobiology, University of Belgrade, Despota Stefana 142, Belgrade, 11060, Serbia.
Jasna BankovicInstitute for Biological Research "Sinisa Stankovic", Department of Neurobiology, University of Belgrade, Despota Stefana 142, Belgrade, 11060, Serbia.
Nikola TanicInstitute for Biological Research "Sinisa Stankovic", Department of Neurobiology, University of Belgrade, Despota Stefana 142, Belgrade, 11060, Serbia.
Milica PesicInstitute for Biological Research "Sinisa Stankovic", Department of Neurobiology, University of Belgrade, Despota Stefana 142, Belgrade, 11060, Serbia.
Tijana StankovicInstitute for Biological Research "Sinisa Stankovic", Department of Neurobiology, University of Belgrade, Despota Stefana 142, Belgrade, 11060, Serbia. tijana.andjelkovic@ibiss.bg.ac.rs.
University of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrent high lung cancer mortality rates are mainly due to the occurrence of metastases and therapeutic resistance. Therefore, simultaneous targeting of these processes may be a valid approach for the treatment of this type of cancer. Here, we assessed relationships between CXC chemokine receptor type 4 (CXCR4) and focal adhesion kinase (FAK) gene expression levels and expression levels of the drug resistance-related genes ABCB1 and ABCC1, and tested the potential of CXCR4 and FAK inhibitors to reverse doxorubicin (DOX) resistance and to decrease the invasive capacity of non-small cell lung carcinoma (NSCLC) cells.

methodsqRT-PCR was used for gene expression analyses in primary lung tissue samples obtained from 30 NSCLC patients and the human NSCLC-derived cell lines NCI-H460, NCI-H460/R and COR-L23. MTT, flow cytometry, cell death and β-galactosidase activity assays were used to assess the in vitro impact of CXCR4 and FAK inhibitors on DOX sensitivity. In addition, invasion and gelatin degradation assays were used to assess the in vitro impact of the respective inhibitors on metastasis-related processes in combination with DOX treatment.

resultsWe found that ABCB1 over-expression was significantly associated with CXCR4 and FAK over-expression, whereas ABCC1 over-expression was associated with increased FAK expression. We also found that CXCR4 and FAK inhibitors strongly synergized with DOX in reducing cell viability, arresting the cell cycle in the S or G

conclusionsFrom our data we conclude that targeting of CXCR4 and FAK may overcome ABCB1 and ABCC1-dependent DOX resistance in NSCLC cells and that simultaneous treatment of these cells with DOX may potentiate the anti-invasive effects of CXCR4 and FAK inhibitors.

Indexed as

AminopyridinesAntineoplastic Combined Chemotherapy ProtocolsATP-Binding Cassette, Sub-Family C ProteinsATP Binding Cassette Transporter, Subfamily BBenzylaminesBlotting, WesternCarcinoma, Non-Small-Cell LungDoxorubicinDrug Resistance, NeoplasmFocal Adhesion Kinase 1Gene Expression ProfilingHumansLung NeoplasmsNeoplasm InvasivenessQuinolonesReal-Time Polymerase Chain Reaction6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-oneABCB1 protein, humanAminopyridinesATP-Binding Cassette, Sub-Family C ProteinsATP Binding Cassette Transporter, Subfamily BBenzylaminesCXCR4 protein, humanDoxorubicinFocal Adhesion Kinase 1multidrug resistance-associated protein 1N,N'-di-2-pyridinyl-1,4-benzenedimethanaminePTK2 protein, humanQuinolonesReceptors, CXCR4SulfonesCXCR4DOXFAKInvasionNon-small cell lung carcinomaResistance

Identifiers

PMID27822706
PMCPMC13001571
OpenAlexW2554446912

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.